Ventana Medical Systems, Inc., a member of the Roche Group, is a world leader and innovator of tissue-based diagnostic solutions for patients worldwide.
Ventana acquired BioImagene in August 2010. Through this acquisition, Ventana is uniquely positioned to deliver an end-to-end solution from automated staining to comprehensive patient reports. Digital Pathology solutions will complement and strengthen Ventana's current offering in image analysis and information management.
Ventana digital pathology, powered by BioImagene, provides complete patient-focused solutions that are optimized for clinical labs worldwide. Ventana's digital pathology solutions represent the next step in improving workflow and efficiencies within pathology laboratories. Our solutions are used in academic medical centers, teaching hospitals, community hospitals, reference laboratories, and pharmaceutical and biotech companies.
Ventana acquired BioImagene in August 2010. Through this acquisition, Ventana is uniquely positioned to deliver an end-to-end solution from automated staining to comprehensive patient reports. Digital Pathology solutions will complement and strengthen Ventana's current offering in image analysis and information management.
Ventana digital pathology, powered by BioImagene, provides complete patient-focused solutions that are optimized for clinical labs worldwide. Ventana's digital pathology solutions represent the next step in improving workflow and efficiencies within pathology laboratories. Our solutions are used in academic medical centers, teaching hospitals, community hospitals, reference laboratories, and pharmaceutical and biotech companies.
Location: United States, California, Sunnyvale
Employees: 51-200
Founded date: 2003
Investors 1
| Date | Name | Website |
| - | Ascension ... | ascensionv... |
Mentions in press and media 1
| Date | Title | Description |
| 19.10.2008 | BioImagene adds Siemens funding for digital pathology | Digital pathology developer BioImagene brought Siemens Venture Capital into its fold last week, adding an unreleased amount to a recently-closed $26 million fourth-round of financing. That round was led by Burill & Co. and included Asce... |